Atossa Therapeutics Inc (ATOS) - סך כל נכסי החברה

The visual representation of quotes for total assets, valued at 48.40, highlights financial pressure resulting from a lack of sales and the threat of failed endoxifen trials. Atossa Therapeutics (ATOS) develops targeted methods for combating breast tumors, relying on costly R&D and patent protection. The business monetization is based on the commercialization of unique drugs whose value has been validated by years of clinical trials.

Investors utilize the scale of resources to assess business resilience during initial screening. This metric is calculated inversely via return on assets (ROA) by summing equity and external liabilities. For Atossa Therapeutics (ATOS), this reflects the funding volume of Stephen Quay's oncology R&D strategy. The trend in total assets allows for a comparison of clinical trial costs against the actual growth of the balance sheet mass.